Direct-to-Consumer Advertising of Prescription Medicines: A Systematic Review of the Evidence from the Perspective of the Consumer

Abstract

Direct-to-consumer advertising of prescription medicines (DTCA) is a controversial practice where many of the arguments for and against are not supported by strong evidence. There is little research that considers DTCA from the consumer's perspective, and this paper explores consumer education, consumer protection, medicalisation of consumer conditions and patient doctor relationships. The paper concludes that little is known about the impact of DTCA on actual consumer behaviour in relation to drug acquisition and use.

Keywords

direct-to-consumer advertising of prescription medicines (DTCA)consumer knowledge attitudes and behaviour medicalisation

References

Huh

Becker

L. B.

(2005). Direct-to-consumer prescription drug advertising: Understanding its consequences. Int. J. Advertising 24(4), 441–466.

Kotler

Keller

K. L.

(2006). Marketing Management, Pearson Prentice Hall, New Jersey.

Khan

K. S.

Riet

Glanville

Sowden

A. J.

Kleijnen

, (eds.) (2001). Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. NHS Centre for Reviews and Dissemination, University of York, York, UK.

Gilbody

Wilson

Watt

(2005). Benefits and harms of direct-to-consumer-advertising: A systematic review. Qual. Safety Healthcare 14, 246–250.

Baukus

(2004). DTC advertising. J. Health Commun. 9(6), 563–564.

White

H. J.

Draves

L. P.

Soong

Moore

(2004). Ask your doctor! Measuring the effect of direct-to-consumer communications in the world's largest healthcare market. Int. J. Advertising 23(1), 53–68.

Neutel

C. I

Walop

(2005). Drug utilization by men and women: Why the difference?. Drug Inform. J. 39(3), 299–311.

Kravitz

R. L.

Epstein

R. M.

Feldman

M. D.

Franz

C. E.

Azari

Wilkes

M. S.

Hinton

Franks

(2005). Influence of patients' requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. JAMA 293(16), 1995–2002.

Pope

(1991). Advertising as a consumer issue: An historical view. J. Soc. Issues 47(1), 41–56.

10.

Palmer

Partners (2000). Consistency of restrictions on medicine advertising with the Bill of Rights Act, memorandum to the Advertising Standards Authority. New Zealand, 5th December.

11.

Cohen

McCubbin

Collin

Perodeu

(2001). Medications as social phenomena. Health 5, 441–469.

12.

Prevention Magazine (2004). Consumer reaction to DTC advertising of prescription medicines — 7th Survey, New York.

13.

Hoek

Gendall

Calfee

(2004). Direct-to-consumer-advertising of prescription medicines in the United States and New Zealand: An analysis of regulatory approaches and consumer responses. Int. J. Advertising 23(2), 197–227.

14.

Berndt

E. R.

(2005). The United States' experience with direct-consumer advertising of prescription drugs what have we learned, Paper presented at the International Conference on Pharmaceutical Innovation, Institute of Economics, Academia Sinica, Grand Hotel, Taipei, Taiwan, May 25–27, Session B4, ‘Consumerism and the Demand for Pharmaceuticals’.

15.

The Advisory Commission on Consumer Protection and Quality in the Health Care Industry. (1998). Quality first: Better healthcare for all Americans. Available from http://www.hcqualitycommission.gov/final/append_a.html accessed 9th October 2006.

16.

Aikin

K. J.

Swasey

J. L.

Braman

A. C.

(2004). Patients and physicians attitudes and behaviors associated with DTC promotion of prescription drugs—summary of FDA survey results. FDA, http://www.fda.gov/cder/ddmac/Final%20Report/DTCPhysicianSurvey%20Materialsb3.pdf#search=%22Patients%20and%20physicians%20attitudes%20and%20behaviors%20associated%20with%20DTC%20promotion%20of%20prescription%20drugs%20%22 accessed 9th October 2006.

17.

ORC International. (2002). Effectiveness of and attitudes toward medication advertising, Consultancy report prepared for NCL.

18.

Deshpande

A. D.

Menon

Perri

III Zinkhan

G. M.

(2004). Direct to consumer advertising and its utility in healthcare decision making. J. Healthcare Commun. 9, 499–513.

19.

Huh

Cude

B. J.

(2004). Is the information ‘fair and balanced’ in direct-to-consumer prescription drug websites?. J. Healthcare Commun. 9, 529–540.

20.

Anantharaman

Anju

Shepherd

(2005). Examination of the relationship between direct-to-consumer-advertising expenditure and price. Drug Inform. J., http://findarticles.com/p/articles/mi_qa3899/is_200501/ai_n13602163 accessed 9th October 2006.

21.

Auton

(2004). The advertising of pharmaceuticals direct-to-consumers: A critical review of the literature and debate. Int. J. Advertising 23(1), 5–52.

22.

United States General Accounting Office (2002). Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. United States General Accounting Office, Washington DC.

23.

Kahn

(2001). How the media influences women's' perceptions of healthcare. Market. Health Serv. 21(1), 13–17.

24.

Calfee

J. E.

(2002). Public policy issues in the direct to consumer advertising of prescription drugs. J. Public Policy Market. 21(2), 174–193.

25.

Lexchin

Mintzes

(2002). Direct-to-consumer-advertising of prescription drugs: The evidence says no. J. Public Policy Market. 21(2), 194–202.

26.

Swann

(2005). Direct-to-consumer-advertising of prescription medication. The Health Report, Radio National, Australia.

27.

Choudry

N. K.

Fletcher

R. H.

Soumerai

S. B.

(2005). Systematic review: The relationship between clinical experience and quality healthcare. Ann. Int. Med. 142(4), 260–273.

28.

Creswell

(2006). Unis producing doctors trained as social workers. The Australian, May 9, p. 8.

29.

Gallagher

T. H.

Levinson

(2004). A prescription for protecting the doctor-patient relationship. Am. J. Manag. Care 10(2), 61–68.

30.

Weissman

J. S.

Blumenthal

Silk

Zapert

Newman

Leitmann

(2003). Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Affairs. Feb 26, available at http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.82v1?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=%09Weissman&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT accessed 8th October 2006.

31.

Bonaccorso

S. N.

Sturchio

J. L.

(2002). Direct-to-consumer-advertising is medicalising normal human experience. Br. Med. J. 324(7432), 910–911.

32.

AusDiab study on obesity and diabetes. (2006). Study commissioned by the International Diabetes Institute reported in The Australian, 15th May, 2006.

33.

Mintzes

(2002). For and against: Direct-to-consumer-advertising is medicalising normal human experience. Br. Med. J. 324(7432), 908–909.

34.

Costa

(2005). Health, the Australian, September 17.

35.

Schneemann

(2005). Far-fetched conclusions taint views on wider medical profession. Health 23. The Australian, 1–2 October.

36.

Conrad

Leiter

(2004). Medicalisation, markets and consumers. J. Health Social Behav. 45, 158–176.

37.

Eagle

Chamberlain

(2004). Prescription medication advertising: Professional discomfort and potential patient benefits — can the two be balanced?. Int. J. Advertising 23(1), 69–90.

38.

Wazana

(2000). Antidepressant puts newborns at risk, study says. National Post, 7th May, A2.

39.

Koch

Y. D.

Ernst

M. E.

Kelly

M. W.

(2002). Patients' perceptions about drug advertising and prescription to non-prescription switching. Am. J. Health Syst. Pharm. 59(16), 1568.

40.

Reast

J. D.

Palihawadana

Spicket-Jones

(2004). UK physicians' attitudes towards direct-to-consumer-advertising of prescription drugs. Int. J. Advertising 23(2), 229–252.

41.

Vatjanapukka

Warszak

(2004). Relationship between consumer knowledge, prescription drug advertising exposure and attitudes to direct-to-consumer prescription advertising. Int. J. Med. Market. 4(4), 350–360.

42.

Miller

Waller

(2004). Attitudes towards DTC advertising in Australia: An exploratory study. Int. J. Advertising 23, 389–405.

43.

Mintzies

Barer

M. L.

Kravitz

R. L.

Bassett

Lexchin

Kanzanjian

Evans

Pan

Marion

S. A.

(2003). How does direct-to-consumer-advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Med. Assoc. J. 169(5), 405–412.

44.

Rosenthal

M. B.

Berndt

E. R.

Donohue

J. M.

Frank

R. G.

Epstein

A. M.

(2002). Promotion of prescription drugs to consumers. New Engl. J. Med. 346(7), 489–505.